ADMA Biologics (NASDAQ:ADMA) Stock Price Down 7%

ADMA Biologics Inc (NASDAQ:ADMA)’s stock price fell 7% during mid-day trading on Tuesday . The stock traded as low as $4.31 and last traded at $4.36, approximately 829,538 shares were traded during mid-day trading. A decline of 5% from the average session volume of 870,786 shares. The stock had previously closed at $4.69.

A number of brokerages have commented on ADMA. Dawson James cut ADMA Biologics from a “buy” rating to a “neutral” rating and set a $4.00 price objective for the company. in a research note on Monday, August 12th. HC Wainwright reaffirmed a “buy” rating and set a $13.00 target price on shares of ADMA Biologics in a research report on Wednesday, November 20th. Maxim Group set a $12.00 target price on ADMA Biologics and gave the stock a “buy” rating in a report on Monday, October 21st. BidaskClub raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Tuesday. Finally, ValuEngine raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Friday, September 20th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $10.20.

The company has a debt-to-equity ratio of 2.33, a quick ratio of 3.76 and a current ratio of 6.42. The company has a market cap of $281.76 million, a price-to-earnings ratio of -3.01 and a beta of 2.66. The stock’s fifty day moving average is $4.55 and its two-hundred day moving average is $4.22.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($0.19) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.04. The business had revenue of $7.22 million for the quarter, compared to analysts’ expectations of $5.71 million. ADMA Biologics had a negative net margin of 260.92% and a negative return on equity of 203.21%. On average, equities research analysts expect that ADMA Biologics Inc will post -0.87 EPS for the current year.

Institutional investors have recently modified their holdings of the company. Jefferies Group LLC bought a new position in shares of ADMA Biologics in the second quarter valued at approximately $2,961,000. Ardsley Advisory Partners LP raised its position in ADMA Biologics by 67.4% in the 2nd quarter. Ardsley Advisory Partners LP now owns 102,608 shares of the biotechnology company’s stock valued at $397,000 after buying an additional 41,308 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in ADMA Biologics by 35.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 82,176 shares of the biotechnology company’s stock valued at $317,000 after acquiring an additional 21,545 shares in the last quarter. H D Vest Advisory Services lifted its stake in ADMA Biologics by 35.0% during the 2nd quarter. H D Vest Advisory Services now owns 135,050 shares of the biotechnology company’s stock valued at $523,000 after acquiring an additional 35,000 shares in the last quarter. Finally, Marshall Wace North America L.P. purchased a new position in ADMA Biologics during the 2nd quarter worth $1,128,000. 62.75% of the stock is owned by hedge funds and other institutional investors.

About ADMA Biologics (NASDAQ:ADMA)

ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Further Reading: What is a support level?

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.